Sarcomas

An NDA seeking the approval of varegacestat for the treatment of adult patients with desmoid tumors has been submitted to the FDA.

Vinayak Venkataraman, MD, spotlights a focus-group study identifying mobility, autonomy, and supportive care gaps in AYA patients with sarcoma.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.

R. Lor Randall, MD, FACS, discusses the rationale of a meta-analysis comparing IM nailing and EP reconstruction for patients with bone metastases.

The CSF-1R–targeting monoclonal antibody emactuzumab met key end points in the phase 3 TANGENT study, setting the stage for a BLA submission.

R. Lor Randall, MD, FACS, highlights a recent meta-analysis comparing 2 approaches to surgical management for patients with femoral metastases.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Cogent Biosciences has submitted an NDA for bezuclastinib for patients with GIST who received prior imatinib.

R. Lor Randall, MD, FACS, discusses how the BOOM consensus provides a global standard for managing complex infections in orthopedic oncology.

R. Lor Randall, MD, FACS, highlights primary objectives of, and key takeaways from, the BOOM consensus meeting on PJI management in orthopedic oncology.

However, a trend towards OS benefit was observed when treatment with cabozantinib was deferred until after disease progression vs administered upfront.

A drug withdrawal in follicular lymphoma and epithelioid sarcoma, a CRL in lung cancer, and priority review in breast cancer highlight this week's top oncology news.

The FDA indications for tazemetostat in relapsed/refractory follicular lymphoma and epithelioid sarcoma are being voluntarily withdrawn.

R. Lor Randall, MD, FACS, discusses a report on factors predicting local recurrence in nonmetastatic Ewing sarcoma from the phase 3 AEWS1031 trial.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

Philippos Costa, MD, and Hari Deshpande, MD, answer common questions about chondrosarcoma staging, diagnosis, surgery, and future research avenues.

The FDA granted priority review to Dato-DXd in triple-negative breast cancer, accepted an NDA for zanzalintinib plus atezolizumab in mCRC, and more.

Philippos Costa, MD, and Hari Deshpande, MD, discuss chondrosarcoma staging, diagnosis, surgery, and future research avenues in this clinician-focused FAQ.

OS Therapies began a rolling submission of a BLA for OST-HER2 in fully resected pulmonary metastatic osteosarcoma.

The clinical benefit and disease control rates were both 100% with lurbinectedin plus ipilimumab/nivolumab in patients with advanced soft tissue sarcoma.

Treatment with first-line metronomic cyclophosphamide did not significantly improve TTF, PFS, or OS vs doxorubicin in advanced soft tissue sarcoma.

HS-20093 demonstrated durable responses and disease control in relapsed/refractory osteosarcoma and STS in phase 2 ARTEMIS-002 trial data presented at ESMO 2025.

Legubicin significantly improved PFS vs doxorubicin in advanced soft tissue sarcoma, with reduced cardiotoxicity and consistent benefit across subgroups.

Toripalimab and chidamide demonstrated particularly notable efficacy outcomes in well-differentiated liposarcoma and dedifferentiated liposarcoma.